Vimarsana
Biggest News Aggregation in the World

Anticipated Runway News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anticipated Runway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anticipated Runway Today - Breaking & Trending Today

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones - Vimarsana News

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Published: March 26, 2024

Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy Expected in mid-2024, a Global...

Source: marketscreener.com
Related Topics:
Joyce AllaireSheryl SeapyInternational Guillain BarrSecurities ExchangeClinical Program UpdatesEuropean Medicines AgencyAnnexon IncDrug AdministrationPivotal PhaseSecond QuarterGeographic AtrophyPrimary Outcome MeasureProof Of Concept DataClassical Pathway ExpectedSecond HalfBalance SheetCash EquivalentsShort Term InvestmentsAnticipated RunwayDouglas LoveSyndrome Outcomes StudyBiologics License ApplicationFast TrackPriority MedicineCold Agglutinin Disease
Viracta Therapeutics Announces First Clinical Response in - Vimarsana News

Viracta Therapeutics Announces First Clinical Response in

Published: January 8, 2023

Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV+ recurrent/metastatic (R/M) nasopharyngeal...

Source: globenewswire.com
Related Topics:
Mark RotheraAshleigh BarretoSilicon Valley BankOncology CongressHead Of Investor Relations Corporate CommunicationsEuropean Society For Medical Oncology ImmunoOxford FinanceViracta Therapeutics IncChief Executive OfficerEuropean SocietyMedical Oncology Immuno CongressAnticipated RunwayViracta TherapeuticsPrivate Securities Litigation Reform ActRelations ContactInvestor RelationsNasdaq VirxViracta Therapeutics